Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
Carcinogenesis|September 18, 2004
Elevated polyamines lead to selective induction of apoptosis and inhibition of tumorigenesis by (-)-epigallocatechin-3-gallate (EGCG) in ODC/Ras transgenic miceBarry Paul, Candace S Hayes, Arianna Kim, et al.Journal of Biopharmaceutical Statistics|September 15, 2015
Nine-year change in statistical design, profile, and success rates of Phase II oncology trialsAnastasia Ivanova, Barry Paul, Olga Marchenko, et al.Expert Opinion on Biological Therapy|August 5, 2020
Daratumumab subcutaneous formulation for the treatment of multiple myelomaBarry Paul, Issam Hamadeh, Shebli Atrash, et al.Expert Review of Hematology|July 14, 2020
An evaluation of subcutaneous daratumumab for the treatment of multiple myelomaBarry Paul, Shebli Atrash, Manisha Bhutani, et al.Cancer Research|August 17, 2006
Tip60 protein isoforms and altered function in skin and tumors that overexpress ornithine decarboxylaseCheryl A Hobbs, Gang Wei, Karen DeFeo, et al.JCO Oncology Practice|April 3, 2020
Gamma Gap: A Point-of-Care Test That Correlates With Disease Burden and Treatment Response in Multiple MyelomaMegan M Dupuis, Barry Paul, Gavin Loitsch, et al.Journal of Hematology|March 10, 2023
Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and DexamethasoneOmar Alkharabsheh, Polina Bellman, Zahra Mahmoudjafari, et al.Cancers|October 14, 2023
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple MyelomaAimaz Afrough, Shebli Atrash, Barry Paul, et al.Cancer Letters|July 25, 2022
PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivoYonggang Sha, Jian Wu, Barry Paul, et al.Cancer Medicine|July 7, 2020
The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitorsBarry Paul, Yue Zhao, Gavin Loitsch, et al.Pageof 5